Hikma Pharmaceuticals PLC
HIK.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.26 | 0.02 | -0.38 |
| FCF Yield | 1.53% | 4.88% | 2.44% | 5.93% |
| EV / EBITDA | 28.57 | 23.09 | 12.67 | 17.56 |
| Quality | ||||
| ROIC | 5.00% | 5.46% | 7.58% | 6.84% |
| Gross Margin | 43.12% | 42.30% | 48.18% | 47.79% |
| Cash Conversion Ratio | – | 2.75 | 0.88 | 6.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.73% | 9.69% | 9.07% | 8.03% |
| Free Cash Flow Growth | -65.56% | 109.30% | -57.14% | 118.12% |
| Safety | ||||
| Net Debt / EBITDA | 5.07 | 3.88 | 2.08 | 2.86 |
| Interest Coverage | 6.48 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.87 | 0.91 | 0.87 | 0.85 |
| Cash Conversion Cycle | 102.98 | 115.15 | 97.47 | 118.33 |